蘇常柴A(000570.SZ):擬減持144萬股聯測科技股票、100.61萬股凱龍高科股票
格隆匯4月11日丨蘇常柴A(000570.SZ)公佈,公司董事會擬授權公司全資子公司常州厚生投資有限公司(稱“厚生投資”)經理層在2023年12月31日前,通過交易所競價交易系統和大宗交易系統,根據二級市場股價走勢,擇機出售其持有的144萬股江蘇聯測機電科技股份有限公司(稱“聯測科技”)股票、100.61萬股凱龍高科技股份有限公司(稱“凱龍高科”)股票。本次擬出售部分交易性金融資產事項尚無確定交易對象,不涉及關聯交易,也不會構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.